{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T03:31:03Z","timestamp":1778643063537,"version":"3.51.4"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T00:00:00Z","timestamp":1746662400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100007434","name":"Suzuken Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007434","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["20K20161, 22K18203"],"award-info":[{"award-number":["20K20161, 22K18203"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["21K18319, 23H00543"],"award-info":[{"award-number":["21K18319, 23H00543"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-99602-8","type":"journal-article","created":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T09:13:15Z","timestamp":1746695595000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Optimization of lymphatic drug delivery system with carboplatin for metastatic lymph nodes"],"prefix":"10.1038","volume":"15","author":[{"given":"Miriu","family":"Miyatsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariunbuyan","family":"Sukhbaatar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radhika","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arunkumar","family":"Dorai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiro","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,8]]},"reference":[{"key":"99602_CR1","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1038\/nrc1370","volume":"4","author":"K Pantel","year":"2004","unstructured":"Pantel, K. & Brakenhoff, R. H. Dissecting the metastatic cascade. Nat. Rev. Cancer. 4, 448\u2013456 (2004).","journal-title":"Nat. Rev. Cancer."},{"key":"99602_CR2","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/nrc1693","volume":"5","author":"Y Cao","year":"2005","unstructured":"Cao, Y. Opinion: Emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat. Rev. Cancer. 5, 735\u2013743 (2005).","journal-title":"Nat. Rev. Cancer."},{"key":"99602_CR3","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1111\/j.1582-4934.2009.00834.x","volume":"13","author":"V Mumprecht","year":"2009","unstructured":"Mumprecht, V. & Detmar, M. Lymphangiogenesis and cancer metastasis. J. Cell Mol. Med. 13, 1405\u20131416 (2009).","journal-title":"J. Cell Mol. Med."},{"key":"99602_CR4","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1517\/17425240903085128","volume":"6","author":"Y Xie","year":"2009","unstructured":"Xie, Y., Bagby, T. R., Cohen, M. S. & Forrest, M. L. Drug delivery to the lymphatic system: Importance in future cancer diagnosis and therapies. Expert Opin. Drug Deliv. 6, 785\u2013792 (2009).","journal-title":"Expert Opin. Drug Deliv."},{"key":"99602_CR5","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1111\/cas.13206","volume":"108","author":"M Mikada","year":"2017","unstructured":"Mikada, M. et al. Evaluation of the enhanced permeability and retention effect in the early stages of lymph node metastasis. Cancer Sci. 108, 846\u2013852 (2017).","journal-title":"Cancer Sci."},{"key":"99602_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(01)00150-8","volume":"50","author":"MA Swartz","year":"2001","unstructured":"Swartz, M. A. The physiology of the lymphatic system. Adv. Drug Deliv. Rev. 50, 3\u201320 (2001).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"99602_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/cas.12873","volume":"107","author":"Y Miura","year":"2016","unstructured":"Miura, Y. et al. Early diagnosis of lymph node metastasis: Importance of intranodal pressures. Cancer Sci. 107, 224\u2013232 (2016).","journal-title":"Cancer Sci."},{"key":"99602_CR8","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv155","author":"HS Jeong","year":"2015","unstructured":"Jeong, H. S. et al. Investigation of the lack of angiogenesis in the formation of lymph node metastases. J. Natl. Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djv155 (2015).","journal-title":"J. Natl. Cancer Inst."},{"key":"99602_CR9","doi-asserted-by":"publisher","first-page":"32506","DOI":"10.1038\/srep32506","volume":"6","author":"T Kodama","year":"2016","unstructured":"Kodama, T., Matsuki, D., Tada, A., Takeda, K. & Mori, S. New concept for the prevention and treatment of metastatic lymph nodes using chemotherapy administered via the lymphatic network. Sci. Rep. 6, 32506 (2016).","journal-title":"Sci. Rep."},{"key":"99602_CR10","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1111\/cas.13387","volume":"108","author":"A Tada","year":"2017","unstructured":"Tada, A., Horie, S., Mori, S. & Kodama, T. Therapeutic effect of cisplatin given with a lymphatic drug delivery system on false-negative metastatic lymph nodes. Cancer Sci. 108, 2115\u20132121 (2017).","journal-title":"Cancer Sci."},{"key":"99602_CR11","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1002\/cam4.2125","volume":"8","author":"H Fujii","year":"2019","unstructured":"Fujii, H. et al. Treatment of false-negative metastatic lymph nodes by a lymphatic drug delivery system with 5-fluorouracil. Cancer Med. 8, 2241\u20132251 (2019).","journal-title":"Cancer Med."},{"key":"99602_CR12","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1111\/cas.15283","volume":"113","author":"A Sukhbaatar","year":"2022","unstructured":"Sukhbaatar, A., Mori, S. & Kodama, T. Intranodal delivery of modified docetaxel: Innovative therapeutic method to inhibit tumor cell growth in lymph nodes. Cancer Sci. 113, 1125\u20131139 (2022).","journal-title":"Cancer Sci."},{"key":"99602_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115110","volume":"165","author":"A Sukhbaatar","year":"2023","unstructured":"Sukhbaatar, A., Mori, S., Shiga, K. & Kodama, T. Intralymphatic injection of chemotherapy drugs modulated with glucose improves their anticancer effect. Biomed. Pharmacother. 165, 115110 (2023).","journal-title":"Biomed. Pharmacother."},{"key":"99602_CR14","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/cas.15599","volume":"114","author":"R Mishra","year":"2023","unstructured":"Mishra, R. et al. Drug formulation augments the therapeutic response of carboplatin administered through a lymphatic drug delivery system. Cancer Sci. 114, 259\u2013270 (2023).","journal-title":"Cancer Sci."},{"key":"99602_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.116085","volume":"171","author":"A Sukhbaatar","year":"2024","unstructured":"Sukhbaatar, A., Mori, S., Sugiura, T. & Kodama, T. Docetaxel administered through a novel lymphatic drug delivery system (LDDS) improved treatment outcomes for lymph node metastasis. Biomed. Pharmacother. 171, 116085 (2024).","journal-title":"Biomed. Pharmacother."},{"key":"99602_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1023\/A:1008215213739","volume":"9","author":"J Lokich","year":"1998","unstructured":"Lokich, J. & Anderson, N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann. Oncol. 9, 13\u201321 (1998).","journal-title":"Ann. Oncol."},{"key":"99602_CR17","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1590\/S1984-82502014000400004","volume":"50","author":"GFD Sousa","year":"2014","unstructured":"Sousa, G. F. D., Wlodarczyk, S. R. & Monteiro, G. Carboplatin: molecular mechanisms of action associated with chemoresistance. Braz. J. Pharm. Sci. 50, 693\u2013701 (2014).","journal-title":"Braz. J. Pharm. Sci."},{"key":"99602_CR18","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.7150\/thno.69424","volume":"12","author":"C Zhang","year":"2022","unstructured":"Zhang, C., Xu, C., Gao, X. & Yao, Q. Platinum-based drugs for cancer therapy and anti-tumor strategies. Theranostics. 12, 2115\u20132132 (2022).","journal-title":"Theranostics."},{"key":"99602_CR19","doi-asserted-by":"publisher","first-page":"55","DOI":"10.5049\/EBP.2014.12.2.55","volume":"12","author":"GS Oh","year":"2014","unstructured":"Oh, G. S. et al. Cisplatin-induced kidney dysfunction and perspectives on improving treatment strategies. Electrolyte Blood Press. 12, 55\u201365 (2014).","journal-title":"Electrolyte Blood Press."},{"key":"99602_CR20","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.3390\/toxins2112490","volume":"2","author":"RP Miller","year":"2010","unstructured":"Miller, R. P., Tadagavadi, R. K., Ramesh, G. & Reeves, W. B. Mechanisms of Cisplatin nephrotoxicity. Toxins (Basel). 2, 2490\u20132518 (2010).","journal-title":"Toxins (Basel)."},{"key":"99602_CR21","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","volume":"17","author":"L Galluzzi","year":"2020","unstructured":"Galluzzi, L., Humeau, J., Buque, A., Zitvogel, L. & Kroemer, G. Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat. Rev. Clin. Oncol. 17, 725\u2013741 (2020).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"99602_CR22","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/j.1552-4604.1988.tb03134.x","volume":"28","author":"S Oguri","year":"1988","unstructured":"Oguri, S. et al. Clinical pharmacokinetics of carboplatin. J. Clin. Pharmacol. 28, 208\u2013215 (1988).","journal-title":"J. Clin. Pharmacol."},{"key":"99602_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jim.2013.01.004","volume":"389","author":"L Shao","year":"2013","unstructured":"Shao, L. et al. Lymphatic mapping of mice with systemic lymphoproliferative disorder: Usefulness as an inter-lymph node metastasis model of cancer. J. Immunol. Methods. 389, 69\u201378 (2013).","journal-title":"J. Immunol. Methods."},{"key":"99602_CR24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1620\/tjem.220.199","volume":"220","author":"Y Tanaka","year":"2010","unstructured":"Tanaka, Y. et al. Evaluating the role of rheumatoid factors for the development of rheumatoid arthritis in a mouse model with a newly established ELISA system. Tohoku J. Exp. Med. 220, 199\u2013206 (2010).","journal-title":"Tohoku J. Exp. Med."},{"key":"99602_CR25","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1039\/C4RA09735A","volume":"5","author":"W Song","year":"2015","unstructured":"Song, W. et al. Comprehensive studies of pharmacokinetics and biodistribution of indocyanine green and liposomal indocyanine green by multispectral optoacoustic tomography. RSC Adv. 5, 3807\u20133813 (2015).","journal-title":"RSC Adv."},{"key":"99602_CR26","doi-asserted-by":"publisher","first-page":"16029","DOI":"10.1038\/s41598-019-52144-2","volume":"9","author":"A Sukhbaatar","year":"2019","unstructured":"Sukhbaatar, A., Sakamoto, M., Mori, S. & Kodama, T. Analysis of tumor vascularization in a mouse model of metastatic lung cancer. Sci. Rep. 9, 16029 (2019).","journal-title":"Sci. Rep."},{"key":"99602_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/jbio.201700401","volume":"11","author":"H Fujii","year":"2018","unstructured":"Fujii, H., Horie, S., Takeda, K., Mori, S. & Kodama, T. Optimal range of injection rates for a lymphatic drug delivery system. J Biophotonics. 11, e201700401 (2018).","journal-title":"J Biophotonics."},{"key":"99602_CR28","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.tcb.2020.06.003","volume":"30","author":"M St Paul","year":"2020","unstructured":"St Paul, M. & Ohashi, P. S. The roles of CD8(+) t cell subsets in antitumor immunity. Trends Cell Biol. 30, 695\u2013704 (2020).","journal-title":"Trends Cell Biol."},{"key":"99602_CR29","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1084\/jem.180.5.1715","volume":"180","author":"M Croft","year":"1994","unstructured":"Croft, M., Carter, L., Swain, S. L. & Dutton, R. W. Generation of polarized antigen-specific CD8 effector populations: Reciprocal action of interleukin (IL)-4 and IL-12 in promoting type 2 versus type 1 cytokine profiles. J. Exp. Med. 180, 1715\u20131728 (1994).","journal-title":"J. Exp. Med."},{"key":"99602_CR30","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.4049\/jimmunol.167.3.1238","volume":"167","author":"WL Chan","year":"2001","unstructured":"Chan, W. L., Pejnovic, N., Lee, C. A. & Al-Ali, N. A. Human IL-18 receptor and ST2L are stable and selective markers for the respective type 1 and type 2 circulating lymphocytes. J. Immunol. 167, 1238\u20131244 (2001).","journal-title":"J. Immunol."},{"key":"99602_CR31","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1182\/blood-2006-11-058271","volume":"110","author":"Y Yang","year":"2007","unstructured":"Yang, Y., Ochando, J. C., Bromberg, J. S. & Ding, Y. Identification of a distant T-bet enhancer responsive to IL-12\/Stat4 and IFNgamma\/Stat1 signals. Blood 110, 2494\u20132500 (2007).","journal-title":"Blood"},{"key":"99602_CR32","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.1158\/0008-5472.CAN-12-3542","volume":"73","author":"EM Dijkgraaf","year":"2013","unstructured":"Dijkgraaf, E. M. et al. Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironment. Cancer Res. 73, 2480\u20132492 (2013).","journal-title":"Cancer Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-99602-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-99602-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-99602-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T09:13:16Z","timestamp":1746695596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-99602-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,8]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["99602"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-99602-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,8]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Approval of the research protocol by an Institutional Reviewer Board. Approval obtained from the Institutional Animal Care and Use Committee of Tohoku University Animal Studies: All investigations carried out using murine models, including the ARRIVE protocol, were compliant with the guidelines of the Institutional Animal Care and Use Committee of Tohoku University.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"16037"}}